RadNet

RDNT · NASDAQ

$69.65+$0.38 (+0.55%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $69.27

RDNT analyst rating

BuyConsensus of 4 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy4
Hold0
Underperform0
Sell0

12-month price target · 10 analysts

Average $96.52 (+38.6% upside)

Low: $79.79
Now: $69.65
High: $110.25

Upgrades and downgrades

The latest rating actions, newest first

RDNT analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Barclays	Aug 28, 2026	Maintains	Overweight	$65.00 → $79.00	59%
Truist Securities	Aug 11, 2026	Maintains	Buy	$90.00 → $94.00	67%
Barclays	May 20, 2026	Maintains	Overweight	$70.00 → $65.00	59%
Barclays	Apr 21, 2026	Maintains	Overweight	$86.00 → $70.00	59%
Keybanc	Jan 9, 2026	Initiates	Overweight	$92.00	61%
B. Riley Securities	Dec 1, 2025	Maintains	Buy	$71.00 → $87.00	37%
Barclays	Nov 13, 2025	Maintains	Overweight	$79.00 → $86.00	59%
Truist Securities	Nov 12, 2025	Maintains	Buy	$81.00 → $90.00	67%

The case for and against

Updated Feb 9, 2026

Bull case

RadNet Inc. is positioned positively due to its strategic investments in technology, which are expected to enhance productivity and leverage amidst a challenging labor market. The company's joint venture strategy is anticipated to foster volume growth and improve market penetration, significantly contributing to its competitive advantage. Additionally, the strong demand trends and increased volumes in advanced procedure categories are driving margin benefits, as demonstrated by a 100 basis point year-over-year growth in these segments.

Bear case

RadNet faces significant challenges that contribute to a negative outlook on its stock, primarily driven by pressure from potential reimbursement changes, labor difficulties, and the struggle to achieve profitability within its AI segment. Furthermore, while the rollout of the TechLive system has yielded a notable reduction in MRI room closures, the long-term financial impact and effectiveness of this technology remain uncertain. These fundamental issues raise concerns about RadNet's ability to sustainably improve its financial performance in a competitive and evolving healthcare landscape.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.